Compare PTCT & PIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTCT | PIPR |
|---|---|---|
| Founded | 1998 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.8B |
| IPO Year | 2006 | 2003 |
| Metric | PTCT | PIPR |
|---|---|---|
| Price | $69.14 | $78.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 3 |
| Target Price | $80.65 | ★ $91.38 |
| AVG Volume (30 Days) | ★ 915.0K | 358.4K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 2.50% |
| EPS Growth | ★ 264.48 | 54.49 |
| EPS | 7.78 | ★ 15.82 |
| Revenue | $264,734,000.00 | ★ $1,904,217,000.00 |
| Revenue This Year | N/A | $13.14 |
| Revenue Next Year | $19.30 | $13.08 |
| P/E Ratio | $8.71 | ★ $4.92 |
| Revenue Growth | ★ 36.19 | 24.33 |
| 52 Week Low | $35.95 | $72.48 |
| 52 Week High | $87.50 | $380.26 |
| Indicator | PTCT | PIPR |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 13.36 |
| Support Level | $64.00 | $72.48 |
| Resistance Level | $69.23 | $347.70 |
| Average True Range (ATR) | 2.24 | 4.87 |
| MACD | 0.57 | -11.58 |
| Stochastic Oscillator | 81.53 | 2.33 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.